Bivalirudin

REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a virtual key opinion leader (KOL) event focused on its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ platform and the broader RNA interference (RNAi) therapeutics manufacturing landscape on Friday, December 8, 2023, at 10:00 am ET. The event will feature John Maraganore, PhD, Founder and Former Chief Executive Officer of Alnylam Pharmaceuticals, and David Butler, PhD, Chief Technology Officer at Hongene Biotech Corporation. These distinguished experts will discuss the RNAi therapeutics manufacturing landscape and share their perspectives on the potential role of an enzymatic route of synthesis in commercial-scale production. During the event, Codexis management will also provide an overview of the ECO Synthesis™ platform and the associated commercial opportunity. A live Q&A session with all presenters will follow the formal presentations. To register for the event, please click here. A replay of the presentation will be archived in the Investor Relations section of the Company’s website, https://ir.codexis.com, following the event. About John Maraganore, PhD John Maraganore, PhD, served as the founding CEO and a Director of Alnylam from 2002 to 2021, where he built and led the company from early platform research on RNA interference through global approval and commercialization of the first five RNAi therapeutics, creating a whole new class of medicines. At Alnylam, Dr. Maraganore built a leading, global biopharmaceutical company with over 1500 employees in over 20 countries around the world. He led the company’s value creation strategy, building over $25B in market capitalization. Prior to Alnylam, he held scientific and business leadership roles at Millennium Pharmaceuticals, Inc.; at Biogen, Inc. where he invented and led the discovery and development of ANGIOMAX® (bivalirudin); at ZymoGenetics, Inc.; and at the Upjohn Company. Dr. Maraganore is currently the principal and owner of JMM Innovations, LLC. He serves as an advisor to a number of venture and public company investment firms, and as a member of the Board of Directors of multiple publicly traded companies, including Beam Therapeutics, Kymera Therapeutics, ProKidney Corp., and Takeda Pharmaceuticals. He is on the Board of a number of private companies and non-profit organizations, and also serves as a strategic advisor to other public and private biotechnology companies. Finally, Dr. Maraganore is on the Board of the Biotechnology Innovation Organization, or “BIO,” where he was Chair from 2017-2019 and is Chair Emeritus. Dr. Maraganore received his BA, MS, and PhD in biochemistry and molecular biology at the University of Chicago. About David Butler, PhD David Butler, PhD, is the Chief Technology Officer at Hongene Biotech Corporation, a fully integrated supplier of raw materials and contract development and manufacturing organization (CDMO) services to customers in the RNA therapeutics space, the scope of which includes mRNA, vaccines, oligonucleotides, gene editing, gene therapy and diagnostics. Prior to Hongene, Dr. Butler led organizations driving platform discovery and development of oligonucleotide therapeutics as Vice President (VP) and Head of Medicinal Chemistry at Wave Life Sciences, VP and Head of Therapeutics Development at Alltrna, and VP and Head of Chemistry at Korro Bio. He also spent time as a Principal Scientist at Alnylam Pharmaceuticals developing early lipid nanoparticle technologies for small interfering RNA delivery that were the progenitors of those used for messenger RNA related products today. About the ECO Synthesis™ Platform Ribonucleic acid (RNA) as a therapeutic modality has gained tremendous traction in recent years with the growing number of messenger RNA (mRNA) vaccines and small interfering RNA (siRNA) candidates advancing in clinical studies. However, large-scale production of RNA interference (RNAi) therapeutics using traditional chemical synthesis faces complex challenges in nucleic acids quality and quantity, as well as overall economics. With over 450 RNAi therapies currently in clinical development, including more than 40 assets in Phase 2 and Phase 3 clinical trials targeting disease indications impacting millions of patients, RNAi therapeutic demand is projected to outpace current production capabilities by the end of the decade. Codexis’ proprietary ECO Synthesis™ technology platform is being designed to address these scalability and cost limitations by potentially enabling the commercial-scale manufacture of RNAi therapeutics through an enzymatic route. The Company is on track to demonstrate gram-scale synthesis by the end of 2023, where it will demonstrate the preparative-scale manufacture of an oligonucleotide, composed of the modified nucleotide building blocks typically used in RNAi therapeutics, under process-like conditions. About Codexis Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com. Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. To the extent that statements contained in this press release are not descriptions of historical facts, they are forward-looking statements reflecting the current beliefs and expectations of management, including but not limited to statements regarding whether Codexis will be able to, and the timing of it demonstrating gram-scale synthesis with its ECO Synthesis™ technology by the end of 2023; the potential of the ECO Synthesis™ platform, including its ability to be broadly utilized, and it providing an opportunity for Codexis to efficiently capture meaningful market share; and expectations regarding future demand for RNAi technologies. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; if any of its collaborators terminate their development programs under their respective license agreements with Codexis; Codexis may need additional capital in the future in order to expand its business; if Codexis is unable to successfully develop new technology such as its ECO Synthesis™ platform; Codexis' dependence on a limited number of products and customers, and potential adverse effects to Codexis’ business if its customers’ products are not received well in the markets; if Codexis is unable to develop and commercialize new products for its target markets; if competitors and potential competitors who have greater resources and experience than Codexis develop products and technologies that make Codexis’ products and technologies obsolete; if Codexis is unable to accurately forecast financial and operational performance; and market and economic conditions may negatively impact Codexis' business, financial condition and share price. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 27, 2023 and in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on November 3, 2023, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. For More Information Investor ContactCarrie McKim(336) 608-9706ir@codexis.com Media ContactLauren Musto(781) 572-1147media@codexis.com

DUBLIN, Aug. 17, 2023 /PRNewswire/ -- The "Heparin-Induced Thrombocytopenia - Market Insight, Epidemiology and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. Heparin-induced Thrombocytopenia remains a challenging immunological syndrome with potentially severe consequences. This report provides an extensive overview of HIT, from its pathophysiology to treatment options and market dynamics. With a focus on emerging therapies and epidemiological insights, it equips stakeholders with a comprehensive understanding of the HIT landscape, aiding in informed decision-making and the development of effective treatment strategies. Epidemiology and Market Landscape The epidemiological aspect of HIT reveals a significant burden, particularly in the United States, which accounted for around 217,000 cases of HIT testing in the 7MM (Seven Major Markets) in 2022. The US also claimed the largest market share among the 7MM countries, capturing approximately 50% of the total market size in the same year. Veralox Therapeutics: A Promising Player Veralox Therapeutics stands out as a key player in the field, with their investigational therapy VLX-1005 holding potential for treating HIT. This underscores the ongoing efforts to develop new and improved treatments for this life-threatening disorder. Report Insights The comprehensive report on HIT encompasses various facets of the syndrome. It describes the condition's definition, types, risk factors, pathophysiology, and treatment options. The report provides insights into the epidemiology, offering predictions on future growth in diagnosis rates, disease progression, and treatment guidelines. It also delves into the current and emerging therapies, including late-stage and prominent therapies that may impact the treatment landscape and market dynamics. The market analysis segment covers historical and projected market sizes, as well as the market share of therapies. The report offers qualitative insights through SWOT analysis, expert views, and patient journey assessments, which help shape the HIT market in the 7MM. Current Therapies and Drug Chapters Existing therapies for HIT include bivalirudin and argatroban, both of which inhibit thrombin to manage the disorder. Bivalirudin is used intravenously to prevent thrombus formation and is suitable for patients undergoing percutaneous coronary intervention. Argatroban, a synthetic direct thrombin inhibitor, is given intravenously and is particularly useful for individuals with thrombosis and HIT. The report provides an in-depth evaluation of these therapies, including their pharmacological mechanisms, clinical trial details, partnerships, approvals, and pros and cons. Market Outlook and Reimbursement The report underscores the urgency of addressing the dearth of approved therapies for HIT and the potential for market expansion as awareness of the condition increases. The emerging pipeline therapy VLX-1005 presents promise for shifting the HIT treatment landscape positively. Reimbursement strategies vary across countries. The report outlines the processes in the US, EU4 countries, the UK, and Japan, shedding light on the role of organizations such as CMS, IQWIG, G-BA, HAS, AIFA, AEMPS, and NICE. Key Topics Covered 1. Key Insights 2. Report Introduction 3. Heparin-induced Thrombocytopenia (HIT) Market Overview at a Glance 4. Executive Summary of Heparin-induced Thrombocytopenia (HIT) 5. Key Events 6. Disease Background and Overview 7. Treatment of Heparin-induced Thrombocytopenia 8. Methodology 9. Epidemiology and Patient Population 10. Patient Journey 11. Marketed Therapies 12. Emerging Therapies 13. Heparin-induced Thrombocytopenia (HIT): Seven Major Market Analysis 14. KOL Views 15. SWOT Analysis 16. Unmet Needs 17. Market Access and Reimbursement 18. Appendix For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets